ABSTRACT
Prior studies suggested that detection of albumin messenger RNA (mRNA) expression by RNA in situ hybridization (RNA ISH) is a highly sensitive method for identification of hepatocellular carcinomas (HCCs) and intrahepatic cholangiocarcinomas (ICCs)/hepatoid carcinomas, with a diagnostic sensitivity of nearly 100% for HCCs and a range of 45% to 99% for ICCs. [1] [2] [3] [4] [5] Ferrone et al 2 reported that detection of albumin mRNA expression by RNA ISH had close to a 100% diagnostic sensitivity and specificity for HCCs and ICCs. However, more recent studies reported expression of albumin mRNA in a significant number of pancreatic acinar cell carcinomas, 6 some hepatoid carcinomas of nonhepatic organs, and a small portion of carcinomas of the lung, gallbladder, and breast. 5 To further determine the clinical utility of albumin RNA ISH, we investigated the diagnostic sensitivity and specificity of RNAscope (Advanced Cell Diagnostics [ACD], Hayward, California) in the detection of albumin mRNA expression in HCCs, ICCs, and a large number of carcinomas from various organs using both manual and automated staining methods.
Materials and Methods

Construction of Tissue Microarray Blocks
The study was conducted with approval from the institutional review board of Geisinger Health System (Danville, PA). Tissue microarray (TMA) blocks containing 482 cases, including HCCs (n = 37), breast ductal carcinomas (n = 68), lung adenocarcinomas (ADCs) (n = 40), esophageal ADCs (n = 35), pancreatic ADCs (n = 50), urothelial carcinomas (n = 40), endometrial ADCs (n = 40), endocervical ADCs (n = 26), ovarian serous carcinomas (n = 42), papillary renal cell carcinomas (n = 32), mesotheliomas (n = 22), and papillary thyroid carcinomas (n = 50), with two 0.75-mm core punches for each case, were constructed as previously described. 7 In addition, 22 cases of ICC (14 surgical resection and eight needle core biopsy specimens) and 20 normal liver and 20 normal pancreas specimens on TMA sections were included in this study. Hilar carcinomas and Klatskin tumors were regarded as extrahepatic cholangiocarcinomas and excluded from this study.
RNAscope Assays by Manual Method
RNAscope assays using target probes to albumin were performed on the TMA slides described above. RNA probes were designed by ACD to hybridize to albumin mRNA molecules. The target probes to albumin contain 10 pairs of ZZ probes to cover the albumin sequence from nucleotides 2 to 490. The positive/negative control probes Hs-PPIB/DapB (ACD); the RNAscope FFPE 2.0 Reagent Kit, which includes Wash Buffer, Pretreat 1 and 3 Pack, Pretreat 2 Pack, 2.0 and Detection Kit-Brown; and the hybridization oven (HybEZ Oven) were also obtained from ACD.
Briefly, the RNAscope assay is a three-step procedure 8, 9 : step 1, tissues were fixed and permeabilized to allow for target probe access; step 2, target RNA-specific oligonucleotide probes were hybridized to multiple RNA targets; and step 3, multiple signal amplification molecules that each recognize a specific target probe were hybridized. The label probes were conjugated to a horseradish peroxidase molecule for chromogenic reactions (3,3-diaminobenzidine with horseradish peroxidase), and the signals were detected using a standard bright-field microscope.
The detailed staining protocol has been reported previously, 10 including: (1) deparaffinization, (2) pretreatment, (3) target probe hybridization, (4) signal amplification, (5) signal detection, and (6) tissue dehydration and mounting the slides.
RNA Scope Assays by Automated Method
TMA sections containing 37 HCCs and 20 cases of normal liver were also tested for albumin mRNA expression using the Leica Bond III automated staining platform (Leica Biosystems, Buffalo Grove, IL). The RNAscope Leica Systems RNA probe for albumin (RS7752), the same used in the manual process above, and Leica Systems positive probe PPIB (RS7755) were used to run the study. The pretreatment reagents were ordered from Leica Biosystems, and included Bond RNAscope Protease (AR-9773), Bond Epitope Retrieval Solution 2 (AR9640), and RNAscope Detection Kit Brown (Lot 49912). The TMA slides were loaded into the Leica Bond III instrument, and the RNAscope assay was performed for approximately 9 hours, per the manufacturer's staining protocol. The albumin molecule signals were visualized using a standard bright-field microscope.
Interpreting Results
Stained tissues were examined using bright-field microscopy. The semiquantitative scoring system for RNAscope was modified from the vendor's recommendation and the literature 10, 11 : 0 (negative, zero to one dot/ tumor cell or two to three dots/tumor cell in less than 5% of tumor cells), 1+ (two to three dots/tumor cell in over 5% of tumor cells/targeted cells), 2+ (four to 10 dots/tumor cell in over 5% of tumor cells/targeted cells, or >10 dots/tumor cell with or without clusters of the signal in less than 50% of tumor cells/targeted cells), 3+ (>10 dots/tumor cell in over 50% of tumor cells/targeted cells), and 4+ (>10 dots/ tumor cell in over 50% of tumor cells/targeted cells with clusters of the signal). All cases with diffuse staining (3+ or 4+) showed expression of albumin mRNA in over 50% of tumor cells/targeted cells. Normal liver tissue served as a positive control, and lymphoid cells, endothelial cells, and stromal cells served as an internal negative control. Two surgical pathologists (F.L. and H.L.) independently evaluated the slides. If a disagreement occurred, the two pathologists reviewed the case together and reached the final agreement. The interpretation was generally straightforward; therefore, the pathologists' results were compatible with no significant disagreements.
Results
Expression of Albumin mRNA in Neoplasms
The results of RNAscope for albumin using the manual method showed that 36 of 37 (97%) HCCs had detectable mRNA, with diffuse staining (3+ or 4+) in all cases, whereas only one lung ADC showed 3+ staining for albumin. The remaining non-HCC and non-ICC cases were negative for albumin. The albumin-negative HCC case showed poorly differentiated morphology and was negative for both cytokeratin 7 (CK7) and arginase-1 on the TMA slide. However, a repeat stain for arginase-1 on the whole tissue section of the same case showed focal positivity (less than 10% of the tumor). The lung ADC case with expression of albumin was also positive for CK7 and thyroid transcription factor 1, and had no hepatoid histomorphology. Expression of albumin in an example of HCC and the case of lung ADC is shown in ❚Image 1A❚ and ❚Image 1B❚. Fourteen of 22 ICCs (64%) were positive for albumin, with diffuse staining (3+ or 4+) in 10 cases. Among these 22 ICCs, 10 of 14 (71%) resection specimens and four of eight (50%) needle-core biopsy specimens were positive for albumin. Expression of albumin in ICC on a resection specimen and on a biopsy specimen is shown in ❚Image 1C❚ and ❚Image 1D❚, respectively.
Expression of Albumin mRNA in Normal Liver and Pancreatic Acini
All 20 cases of normal liver showed diffuse expression of albumin (4+) in hepatocytes and focal expression (1+ or 2+) in the bile ducts in the portal tracts. Approximately 50% of pancreatic acini demonstrated variable immunoreactivities for albumin, with the majority showing focal expression (1+ or 2+). The positive staining signals in normal pancreatic acini and normal bile ducts are less intense than in normal hepatocytes. Expression of albumin in ductules is generally more diffuse and intense than in normal bile ducts. All pancreatic ducts, islets, and stromal cells were negative for albumin. Expression of albumin in normal hepatocytes, portal bile duct, and benign pancreatic acini is shown in ❚Image 2A❚ and ❚Image 2B❚.
Expression of Albumin mRNA in HCCs and Normal Liver Using an Automated Platform
TMA sections containing 37 HCCs and 20 cases of normal liver were tested for albumin mRNA expression using the Leica Bond III automated platform. The results were identical to those obtained by manual method, which showed 97% of HCCs (36 of 37) and 100% of normal liver cases (20 of 20) to be positive for albumin.
Discussion
Our current study demonstrated that expression of albumin mRNA by RNA ISH (ACD probe) was seen in 97% of HCCs, which was similar to the reports in the literature, 1-3 and 64% of ICCs, which was within the range of reports in the literature (45%-99%). 2, 4 From these limited data, there is strong agreement about the high diagnostic sensitivity of nearly 100% for HCCs. [1] [2] [3] 5 However, there appears to be a significant discrepancy in its diagnostic specificity for nonhepatic carcinomas and sensitivity for ICCs.
2,4,5 Therefore, our discussion focuses on: (1) why the reported albumin mRNA ISH data in the literature were inconsistent, and (2) the utilities and the potential pitfalls when using albumin RNA ISH.
Why were the reported albumin RNA ISH data in the literature inconsistent? As is well known, an entirely sensitive and specific cancer biomarker or diagnostic marker is nearly nonexistent. As expected, a newly discovered or introduced biomarker initially tends to demonstrate a nearly perfect diagnostic sensitivity and specificity for a specific entity; however, over time, the diagnostic sensitivity, and particularly the specificity, will decline following more extensive studies. Many factors may contribute to the inconsistent data, including manual vs automated staining technique, one automated staining platform vs another, different probes and detection kits from different vendors, different staining protocols, TMA vs large tissue sections, various tissue fixation times and processing conditions, and criteria for interpreting results. Additionally, the criteria used in each study to define an ICC vs extrahepatic cholangiocarcinoma were not clear. A few recently published articles will be reviewed and the findings compared.
Shahid et al 1 studied the expression of albumin mRNA in 93 HCCs using both manual and automated staining platforms, and the results demonstrated that 99% (92 of 93) of HCCs were positive for albumin, 39% (36 of 92) of which were poorly differentiated HCCs. The ISH probe for albumin mRNA was obtained from Affymetrix (Santa Clara, CA). A similar study was conducted by Ferron et al 2 and showed that 42 of 42 (100%) HCCs were positive for albumin mRNA by using modified branched DNA probes from Affymetrix. Preliminary results from Avadhani and colleagues 3 showed that 22 of 22 (100%) HCCs were positive for albumin using RNAscope probes and detection kit (ACD) on a Leica automated staining platform. Ten of the 22 HCC cases in their study were poorly differentiated HCCs. 3 Lehrke et al 5 reported that 100% (26 of 26) of HCCs were positive for albumin using probes from both ACD and Affymetrix. Our current study demonstrated a similar finding, with 97% of HCCs (36 of 37) positive for albumin using the probe from ACD on TMA slides. These studies indicate that: (1) the probes for albumin from both ACD and Affymetrix were well designed and highly sensitive for the detection of HCCs; (2) the staining sensitivity was independent of staining method; and (3) tissue size (TMA vs whole slide section) had little negative impact on the diagnostic sensitivity. These studies are summarized in ❚Table 1❚. [1] [2] [3] 5 In contrast, the reported results on ICCs were inconsistent from one study to the another. reported 81.5% (22 of 27) of ICCs to be positive for albumin on whole tissue sections using ACD probes. Our current study showed that 64% of ICCs were positive for albumin using whole tissue sections from both resection and biopsy specimens. The positive reactivity was seen in 71% of ICC cases (10 of 14) when only resection specimens were counted. As aforementioned, the probe (ACD vs Affymetrix), the staining platform (manual vs automated), and the tissue size (TMA vs whole tissue section) had little negative impact on the albumin detection in HCCs. The detailed results from these studies are summarized in ❚Table 2❚. expression of albumin. Perhaps, if an ICC originates from the stem cells within peribiliary glands, it may share a closer immunophenotype to that of an extrahepatic cholangiocarcinoma, which is typically negative for albumin.
Similarly, the results in the literature for nonhepatic neoplasms were inconsistent. Ferrone et al 2 reported
that none of 332 nonhepatic carcinomas from the perihilar region, bile duct, pancreas, stomach, esophagus, colon, breast, ovary, endometrium, kidney, and bladder were positive for albumin. The study by Askan and colleagues 6 demonstrated 25% (five of 20) of pancreatic acinar cell carcinomas (acinar cell carcinomas; six pure ❚Image 2❚ A and B, Expression of albumin in normal hepatocytes and portal bile duct (A, ×400) and benign pancreatic acini (B, ×400). Note the weak and focal staining (low level of expression) in portal bile ducts. acinar cell carcinomas and 14 mixed acinar neoplasms), to be positive for albumin. In the study by Lehrke et al, 5 156 nonhepatic neoplasms on whole tissue sections were included and the results showed the following positive findings: 23% of lung ADCs (three of 13), 39% of gallbladder ADCs (five of 13), 9% of breast carcinomas (one of 11), 25% of yolk sac tumors (two of eight), 33% of pancreatic acinar cell carcinomas (two of six), and 33% of hepatoid carcinomas (one of three). Our current study included 445 nonhepatic neoplasms from various organs on TMA sections, and only one lung ADC was positive for albumin, as shown in Image 1B. Clearly, expression of albumin mRNA is not entirely sensitive and specific for the detection of HCC or ICC. To improve the diagnostic sensitivity and specificity and avoid the potential pitfalls, a small panel of IHC markers should be considered. Depending upon the differential diagnoses, markers such as arginase-1, hepatocyte paraffin antigen 1, and glypican-3 can be useful. 7, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] In summary, RNAscope for albumin is a highly sensitive and specific method for identifying HCCs and is a highly specific and moderately sensitive method for detection of ICCs when it is included in a panel of IHC markers to distinguish ICC from other metastatic carcinomas from the pancreas and extrahepatic biliary and upper gastrointestinal tract. However, caution should be taken because a significant percentage of acinar cell carcinomas of the pancreas and rare carcinomas (non-HCC, non-ICC, and those with no hepatoid histomorphology) can also have aberrant expression of albumin.
